Lonza to acquire Synaffix to strengthen ADC development
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services
Read Moreby Jen Brogan | Jun 1, 2023 | News | 0
Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services
Read Moreby John Pinching | Jun 30, 2022 | News | 0
Centre will accelerate drug development and enable precision health solutions
Read Moreby John Pinching | Apr 6, 2022 | News | 0
New Dublin development office will be responsible for paediatric clinical trials for seven products across 18 countries
Read Moreby Lucy Parsons | Aug 19, 2021 | News | 0
Option is a collaboration between BMS and AI-driven pharmatech Exscientia
Read Moreby Lucy Parsons | Mar 2, 2021 | News | 0
Focus of the agreement is a first-in-class small molecule adenosine A2B receptor antagonist
Read Moreby Anna Smith | Jul 1, 2019 | News | 0
The charity is partnering with NRG Therapeutics Ltd to discover and develop a potential drug that could safeguard dopamine cells.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479